Antilipidemic Drugs

Correct Answer

C — Evolocumab and alirocumab

Rationale

Evolocumab and alirocumab are both classified as monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors administered by subcutaneous injection on a biweekly or monthly schedule. Evolocumab is given as 140 milligrams every two weeks or 420 milligrams once monthly. Alirocumab is given as 75 to 150 milligrams every two weeks or 300 milligrams monthly. Inclisiran is also a proprotein convertase subtilisin/kexin type 9 pathway inhibitor administered by subcutaneous injection, but its schedule is distinctly different — it is given at day one, at three months, and then every six months thereafter, making it a twice-yearly agent rather than a biweekly or monthly one.

Correct Answer

A — Inclisiran

Rationale

Inclisiran is classified as the proprotein convertase subtilisin/kexin type 9 pathway inhibitor administered twice yearly after an initial loading phase. The dosing schedule is day one, at three months, and then every six months thereafter — two injections per year during the maintenance phase. This twice-yearly schedule is inclisiran's defining clinical differentiator from the monoclonal antibodies. Evolocumab is given every two weeks or once monthly. Alirocumab is given every two weeks or monthly. Ezetimibe is an oral agent taken daily and is not a proprotein convertase subtilisin/kexin type 9 pathway inhibitor.

Correct Answer

D — Monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors

Rationale

Monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors — evolocumab and alirocumab — are large protein molecules classified as being eliminated through normal protein catabolism pathways rather than cytochrome P450 enzymes. Because they are not substrates for cytochrome P450 enzymes, they have no cytochrome P450-mediated drug interactions and require no dose adjustment for hepatic or renal impairment. Statins are eliminated primarily via cytochrome P450 3A4 or cytochrome P450 2C9 depending on the agent. Fibrates are metabolized via glucuronidation and other non-cytochrome P450 pathways but are not protein molecules. Ezetimibe undergoes minimal cytochrome P450 metabolism and is mainly eliminated by glucuronidation, not protein catabolism.

Correct Answer

B — Ezetimibe

Rationale

Ezetimibe is classified as having no clinically relevant cytochrome P450 drug interactions. It is minimally metabolized by cytochrome P450 enzymes and is instead primarily eliminated by glucuronidation, giving it an extremely low drug-drug interaction profile. This makes ezetimibe safe to combine with drugs that are potent cytochrome P450 inhibitors or inducers without concern for pharmacokinetic interactions. Atorvastatin and simvastatin are both cytochrome P450 3A4 substrates and carry well-documented interaction risks with cytochrome P450 3A4 inhibitors such as azole antifungals and macrolide antibiotics. Fluvastatin is a cytochrome P450 2C9 substrate and interacts with cytochrome P450 2C9 inhibitors such as fluconazole.

Correct Answer

C — Niacin

Rationale

Niacin is classified as a GPR109A receptor agonist. GPR109A is a G-protein-coupled receptor expressed on adipocytes; niacin's activation of this receptor inhibits adipose tissue lipolysis, reducing the delivery of free fatty acids to the liver and thereby decreasing hepatic very low-density lipoprotein synthesis and triglyceride production. Fenofibrate is classified as a peroxisome proliferator-activated receptor-alpha agonist, not a GPR109A agonist. Ezetimibe is classified as a Niemann-Pick C1-Like 1 transporter inhibitor. Colesevelam is classified as a bile acid sequestrant.

Correct Answer

A — Bempedoic acid

Rationale

Bempedoic acid is classified as an adenosine triphosphate-citrate lyase inhibitor. Adenosine triphosphate-citrate lyase is an enzyme in the cholesterol synthesis pathway located upstream of 3-hydroxy-3-methylglutaryl coenzyme A reductase — the enzyme that statins inhibit. Ezetimibe is classified as a Niemann-Pick C1-Like 1 transporter inhibitor. Fenofibrate is classified as a peroxisome proliferator-activated receptor-alpha agonist. Inclisiran is classified as a small interfering ribonucleic acid agent targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid.

Correct Answer

B — Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 sterol transporter, which moves only cholesterol across the brush border; triglycerides and fat-soluble vitamins are absorbed through separate pathways that Niemann-Pick C1-Like 1 does not mediate

Rationale

The Niemann-Pick C1-Like 1 protein is a sterol-specific transporter located on the intestinal brush border. Its function is limited to moving cholesterol — both dietary and biliary — across the enterocyte membrane. Triglycerides are absorbed as monoglycerides and fatty acids after lipolysis and enter enterocytes through separate fatty acid transport mechanisms; fat-soluble vitamins (A, D, E, and K) are incorporated into mixed micelles and absorbed by passive diffusion or distinct transporters. Because ezetimibe targets only Niemann-Pick C1-Like 1, it leaves all of these other absorption pathways intact. Bile acid sequestrants, by contrast, bind bile acids in the lumen and disrupt the formation of mixed micelles that are required for absorption of fat-soluble vitamins and fat-soluble drugs — a broader and less selective mechanism of action.

Correct Answer

D — It provided genetic proof of concept that blocking proprotein convertase subtilisin/kexin type 9 would be both effective at lowering low-density lipoprotein cholesterol and safe to do so over a lifetime, validating proprotein convertase subtilisin/kexin type 9 as a therapeutic target before any drug existed

Rationale

The discovery that people with naturally occurring loss-of-function mutations in proprotein convertase subtilisin/kexin type 9 live with very low low-density lipoprotein cholesterol for their entire lives — and have dramatically lower rates of coronary heart disease with no apparent harm — provided the pharmacological community with compelling genetic validation of the target before any inhibitor was developed. It demonstrated simultaneously that blocking proprotein convertase subtilisin/kexin type 9 would lower low-density lipoprotein cholesterol substantially, that the degree of lowering would be cardiovascular-protective, and that lifelong absence of proprotein convertase subtilisin/kexin type 9 function is well tolerated in humans. This is an example of human genetic evidence guiding drug development and providing an unusually strong safety and efficacy signal prior to clinical trials. The finding had no direct bearing on the route of administration of resulting drugs, did not establish a lower limit for safe low-density lipoprotein cholesterol reduction, and did not argue for statins over proprotein convertase subtilisin/kexin type 9 inhibitors.

Correct Answer

A — Alirocumab is initiated at 75 milligrams every two weeks and can be increased to 150 milligrams every two weeks if the low-density lipoprotein cholesterol response is insufficient; evolocumab is given at a fixed dose without titration

Rationale

Alirocumab has a titratable dosing scheme: it is started at 75 milligrams subcutaneously every two weeks, with the option to increase to 150 milligrams every two weeks if the low-density lipoprotein cholesterol target is not achieved. A 300 milligram monthly option is also available. Evolocumab, by contrast, is given at fixed doses — either 140 milligrams every two weeks or 420 milligrams once monthly — without titration based on the low-density lipoprotein cholesterol response. Option B misattributes the titration feature to evolocumab. The 420 milligram monthly option for evolocumab is an alternative fixed schedule, not a higher titrated dose. Inclisiran does not have a dose titration scheme; its maintenance schedule is fixed at twice yearly after the loading phase.

Correct Answer

C — Inclisiran is incorporated into the ribonucleic acid-induced silencing complex inside hepatocytes and degrades proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid before it can be translated into protein; monoclonal antibodies bind the already-secreted proprotein convertase subtilisin/kexin type 9 protein in the bloodstream

Rationale

Inclisiran is a small interfering ribonucleic acid molecule that, after delivery to hepatocytes, is incorporated into the ribonucleic acid-induced silencing complex. This intracellular complex identifies and degrades proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid before it can be translated into protein, preventing the liver from producing proprotein convertase subtilisin/kexin type 9 in the first place. With less proprotein convertase subtilisin/kexin type 9 protein made, more low-density lipoprotein receptors survive on the hepatocyte surface to clear plasma low-density lipoprotein. Evolocumab and alirocumab, by contrast, are monoclonal antibodies that circulate in the bloodstream and bind proprotein convertase subtilisin/kexin type 9 protein after it has already been secreted by the liver, preventing it from interacting with low-density lipoprotein receptors on the hepatocyte surface. Both approaches converge on the same outcome — more functional low-density lipoprotein receptors — but act at different points in the proprotein convertase subtilisin/kexin type 9 production and action pathway.

Correct Answer

B — It was the first trial to show that a non-statin agent reduces cardiovascular events, confirming that the benefit comes from low-density lipoprotein cholesterol reduction itself rather than any mechanism unique to statins

Rationale

IMPROVE-IT was the pivotal cardiovascular outcomes trial for ezetimibe. By demonstrating that adding ezetimibe to statin therapy after acute coronary syndrome reduced major cardiovascular events compared to statin alone, it provided the first proof that non-statin low-density lipoprotein cholesterol lowering reduces cardiovascular events. This was pharmacologically important because it confirmed that the clinical benefit is driven by the degree of low-density lipoprotein cholesterol reduction — not by any mechanism specific to statin drugs such as pleiotropic anti-inflammatory effects. The trial also established that achieving very low low-density lipoprotein cholesterol levels (around 50 milligrams per deciliter) is safe, with no evidence of harm at these levels. Ezetimibe does not replace statins as first-line therapy; it is an add-on agent. The trial found benefit, not harm, at low low-density lipoprotein cholesterol levels.

Correct Answer

D — ODYSSEY OUTCOMES enrolled patients shortly after acute coronary syndrome and demonstrated a reduction in all-cause mortality — the first proprotein convertase subtilisin/kexin type 9 inhibitor trial to show this endpoint

Rationale

ODYSSEY OUTCOMES, the outcomes trial for alirocumab, enrolled patients who had experienced a recent acute coronary syndrome and were on maximally tolerated statin therapy. In addition to reducing major cardiovascular events, it demonstrated a statistically significant reduction in all-cause mortality — the first proprotein convertase subtilisin/kexin type 9 inhibitor trial to show this endpoint. FOURIER, the outcomes trial for evolocumab, enrolled patients with stable established atherosclerotic cardiovascular disease and demonstrated significant reductions in the primary cardiovascular composite endpoint and cardiovascular death, but did not show a statistically significant reduction in all-cause mortality. Both trials achieved unprecedented reductions in low-density lipoprotein cholesterol and demonstrated that very low levels are safe. Neither trial was limited to familial hypercholesterolemia patients, and alirocumab was used at approved doses in ODYSSEY OUTCOMES.

Correct Answer

A — Monoclonal antibodies have established cardiovascular event reduction in large outcomes trials; inclisiran was approved on the basis of low-density lipoprotein cholesterol lowering efficacy alone, with definitive cardiovascular outcomes data still pending at the time of approval

Rationale

When the goal is to reduce cardiovascular events with the greatest confidence — as in the post-acute coronary syndrome period — the strength of outcomes evidence matters. Evolocumab and alirocumab each have large randomized cardiovascular outcomes trials demonstrating significant reductions in major cardiovascular events. Inclisiran was approved by regulatory authorities based on its proven low-density lipoprotein cholesterol lowering efficacy, which is comparable to the monoclonal antibodies at 50 to 55 percent reduction, but at the time of approval its cardiovascular event reduction had not yet been demonstrated in a completed outcomes trial. Both inclisiran and the monoclonal antibodies begin lowering low-density lipoprotein cholesterol within days of the first injection. The difference in preference for urgent settings is driven by the strength of outcomes evidence, not by a clinically meaningful difference in onset of low-density lipoprotein cholesterol lowering. Inclisiran is approved for patients with established atherosclerotic cardiovascular disease — not limited to familial hypercholesterolemia.

Correct Answer

C — The statin reduces hepatic cholesterol synthesis and upregulates low-density lipoprotein receptors; ezetimibe reduces intestinal cholesterol delivery and further upregulates those receptors through a complementary input; the proprotein convertase subtilisin/kexin type 9 inhibitor prevents the upregulated receptors from being degraded — three non-overlapping mechanisms converging on maximum receptor density

Rationale

The pharmacological rationale for triple therapy is mechanistic complementarity at every step. The statin inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase, reducing hepatic cholesterol synthesis and triggering compensatory low-density lipoprotein receptor upregulation. Ezetimibe blocks the Niemann-Pick C1-Like 1 transporter, reducing intestinal cholesterol delivery to the liver and depleting hepatic cholesterol through a completely separate route — activating the same sterol regulatory element-binding protein 2 pathway and driving additional receptor upregulation. The proprotein convertase subtilisin/kexin type 9 inhibitor then prevents the greatly increased number of upregulated receptors from being escorted to lysosomal degradation, dramatically extending their functional lifespan on the hepatocyte surface. Because none of these three mechanisms overlaps with the others, each addition provides genuine incremental low-density lipoprotein cholesterol reduction. The combined effect on plasma low-density lipoprotein clearance can reach 70 to 85 percent below the untreated baseline. The other options misrepresent the mechanisms — ezetimibe does not inhibit squalene synthase, and proprotein convertase subtilisin/kexin type 9 inhibitors do not target lipoprotein(a) as their primary mechanism.

Correct Answer

D — Ezetimibe is inexpensive as a generic agent, has proven cardiovascular outcomes benefit from the IMPROVE-IT trial, acts through a mechanism complementary to statins, and is well tolerated — making it the logical and guideline-endorsed first non-statin addition before escalating to more costly agents

Rationale

Current guidelines recommend a stepwise approach to low-density lipoprotein cholesterol reduction: optimize statin intensity first, then add ezetimibe, and add a proprotein convertase subtilisin/kexin type 9 inhibitor only if the target remains unmet on statin plus ezetimibe. Ezetimibe is placed first in this sequence because it is available as an inexpensive generic, has demonstrated cardiovascular event reduction in the IMPROVE-IT trial, reduces low-density lipoprotein cholesterol by an additional 18 to 25 percent when added to statin therapy through a complementary intestinal mechanism, and has an excellent safety profile. Proprotein convertase subtilisin/kexin type 9 inhibitors are more powerful but substantially more expensive and require prior authorization, making them appropriate after ezetimibe rather than instead of it. Ezetimibe does not block proprotein convertase subtilisin/kexin type 9 — that is a separate mechanism. There is no time restriction on adding proprotein convertase subtilisin/kexin type 9 inhibitors based on duration of prior statin therapy.

Correct Answer

B — Proprotein convertase subtilisin/kexin type 9 inhibitors, which prevent the degradation of low-density lipoprotein receptors and allow the large number of receptors already upregulated by the statin and ezetimibe to recycle to the hepatocyte surface and clear more low-density lipoprotein from the plasma

Rationale

When a patient with heterozygous familial hypercholesterolemia remains above the low-density lipoprotein cholesterol target on maximally tolerated statin plus ezetimibe, the next step per current guidelines is to add a proprotein convertase subtilisin/kexin type 9 inhibitor. Heterozygous familial hypercholesterolemia is one of the approved guideline indications for this drug class. The mechanism of the additional benefit is pharmacologically rational: the statin and ezetimibe have already driven substantial low-density lipoprotein receptor upregulation through two complementary pathways, but the counterregulatory rise in proprotein convertase subtilisin/kexin type 9 caused by both agents limits how long each receptor survives on the hepatocyte surface. A proprotein convertase subtilisin/kexin type 9 inhibitor prevents this receptor degradation, allowing the large pool of upregulated receptors to recycle continuously and dramatically amplify low-density lipoprotein clearance. Fibrates lower triglycerides but have minimal effect on low-density lipoprotein cholesterol in familial hypercholesterolemia. Bile acid sequestrants provide only 15 to 25 percent additional low-density lipoprotein reduction and are unlikely to bring this patient to goal. Niacin provides little low-density lipoprotein cholesterol reduction and has been abandoned for cardiovascular risk reduction given negative outcomes trials on statin background.

Correct Answer

A — Monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors have proven cardiovascular event reduction in large outcomes trials; inclisiran was approved based on low-density lipoprotein cholesterol lowering efficacy with cardiovascular outcomes data still pending, making the monoclonal antibodies the stronger evidence-based choice when outcomes evidence matters most

Rationale

In the acute coronary syndrome setting — where the clinical goal is not only to lower low-density lipoprotein cholesterol but to reduce the risk of recurrent cardiovascular events — the strength of cardiovascular outcomes evidence is a critical selection criterion. Evolocumab and alirocumab each have large randomized trials demonstrating reductions in major cardiovascular events, with alirocumab also demonstrating all-cause mortality reduction in a post-acute coronary syndrome population. Inclisiran reduces low-density lipoprotein cholesterol by a comparable 50 to 55 percent but at the time of its approval, definitive cardiovascular event reduction had not been demonstrated. Both drug classes begin lowering low-density lipoprotein cholesterol within days of the first injection, so onset of action does not drive the preference. Inclisiran has no contraindication related to prior myocardial infarction, and its administration does not require a certified specialist.

Correct Answer

C — Bempedoic acid, because the enzyme that converts it to its active form is present in the liver but absent in skeletal muscle, so the drug is not activated in muscle tissue and cannot cause muscle toxicity

Rationale

Bempedoic acid is a prodrug that requires activation by a liver-specific enzyme — very long chain acyl-coenzyme A synthetase 1 — that is present in the liver but absent in skeletal muscle. Because bempedoic acid is not converted to its active inhibitory form in muscle tissue, it cannot inhibit adenosine triphosphate-citrate lyase in skeletal muscle and therefore does not cause statin-like muscle toxicity. This makes it particularly appropriate for patients with confirmed statin intolerance who need additional low-density lipoprotein cholesterol reduction. Bempedoic acid reduces low-density lipoprotein cholesterol by approximately 18 to 21 percent as monotherapy and has established cardiovascular outcomes evidence in statin-intolerant patients. Ezetimibe is absorbed systemically but does not cause muscle toxicity; however, its freedom from myotoxicity is not explained by intestinal confinement. Niacin has been largely abandoned for cardiovascular risk reduction due to negative outcomes trials and significant adverse effects including flushing and new-onset diabetes. Colesevelam lowers low-density lipoprotein cholesterol only modestly and is not the preferred agent when bempedoic acid is available for a statin-intolerant patient requiring meaningful low-density lipoprotein cholesterol reduction.